Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction

• Published in: Clinical and molecular hepatology 2024, 30(3), , pp.539-560
• Main Authors: Dezhbord, Mehrangiz, Kim, Seong Ho, Park, Soree, Lee, Da Rae, Kim, Nayeon, Won, Juhee, Lee, Ah Ram, Kim, Dong-Sik, Kim, Kyun-Hwan
• Format: Article
• Language: English
• Subjects: Animals; Carcinoma, Hepatocellular - metabolism; Carcinoma, Hepatocellular - pathology; Carcinoma, Hepatocellular - virology; DNA, Viral - metabolism; hbv x protein; Hep G2 Cells; Hepatitis B; Hepatitis B - metabolism; hepatitis b virus; Hepatitis B virus - physiology; hepatocyte nuclear factor; Hepatocyte Nuclear Factor 1-alpha - genetics; Hepatocyte Nuclear Factor 1-alpha - metabolism; Hepatocyte Nuclear Factor 4 - genetics; Hepatocyte Nuclear Factor 4 - metabolism; Hepatocytes - cytology; Hepatocytes - metabolism; Hepatocytes - virology; Humans; Infections; interferon-gamma; Interferon-gamma - metabolism; Kinases; Liver cancer; Liver Neoplasms - metabolism; Liver Neoplasms - pathology; Liver Neoplasms - virology; Membranes; mhc class ii transactivator; Mice; Nuclear Proteins - genetics; Nuclear Proteins - metabolism; Original; Penicillin; Phenols; Plasmids; Polyethylene glycol; Trans-Activators - genetics; Trans-Activators - metabolism; Tumor necrosis factor-TNF; Viral Regulatory and Accessory Proteins; Virus Replication; 내과학
• ISSN: 2287-2728; 2287-285X; 2287-285X
• DOI: 10.3350/cmh.2024.0060

The major histocompatibility class II (MHC II) transactivator, known as CIITA, is induced by Interferon gamma (IFN-γ) and plays a well-established role in regulating the expression of class II MHC molecules in antigen-presenting cells. Primary human hepatocytes (PHH) were isolated via therapeutic hepatectomy from two donors. The hepatocellular carcinoma (HCC) cell lines HepG2 and Huh7 were used for the mechanistic study, and HBV infection was performed in HepG2-NTCP cells. HBV DNA replication intermediates and secreted antigen levels were measured using Southern blotting and ELISA, respectively. We identified a non-canonical function of CIITA in the inhibition of hepatitis B virus (HBV) replication in both HCC cells and patient-derived PHH. Notably, in vivo experiments demonstrated that HBV DNA and secreted antigen levels were significantly decreased in mice injected with the CIITA construct. Mechanistically, CIITA inhibited HBV transcription and replication by suppressing the activity of HBV-specific enhancers/promoters. Indeed, CIITA exerts antiviral activity in hepatocytes through ERK1/2-mediated down-regulation of the expression of hepatocyte nuclear factor 1α (HNF1α) and HNF4α, which are essential factors for virus replication. In addition, silencing of CIITA significantly abolished the IFN-γ-mediated anti-HBV activity, suggesting that CIITA mediates the anti-HBV activity of IFN-γ to some extent. HBV X protein (HBx) counteracts the antiviral activity of CIITA via direct binding and impairing its function. Our findings reveal a novel antiviral mechanism of CIITA that involves the modulation of the ERK pathway to restrict HBV transcription. Additionally, our results suggest the possibility of a new immune avoidance mechanism involving HBx.